Stanford University
Showing 101-110 of 573 Results
-
Arianne Caudal
Instructor, Cardiovascular Institute
BioDr. Arianne Caudal is a postdoctoral fellow at the Stanford Cardiovascular Institute with research interests in cardiac metabolism, disease modeling, and drug discovery. Dr. Caudal received her PhD in Biochemistry from the University of Washington, after conducting thesis work on mitochondrial metabolism and protein-protein interactions in the heart.
-
Alejandro Sebastian Cazzulino
Clinical Instructor, Orthopaedic Surgery
BioI am originally from New York City. I went to Columbia University, where I earned my BA in Neuroscience and Behavior. I then went to the Perelman School of Medicine at the University of Pennsylvania, where I earned my MD. I then moved to the West Coast and completed my orthopedic surgery residency training at the University of California, San Francisco (UCSF). I am now an Adult Reconstruction Fellow in the Department of Orthopedic Surgery at Stanford University.
-
Lynette Cegelski
Monroe E. Spaght Professor of Chemistry and Professor, by courtesy, of Chemical Engineering
Current Research and Scholarly InterestsOur laboratory uncovers the chemical principles that organize living systems. Across biology - from microbial communities to human disease - chemical and macromolecular composition, molecular interactions, and chemical modifications govern the assembly, function, and persistence of complex biological systems, yet many of these principles remain hidden from conventional approaches. We develop innovative chemical, structural, and biological strategies to preserve and interrogate intact biological systems, revealing chemistry that cannot be observed by studying isolated components alone. Our work has uncovered previously unknown molecular structures, chemical modifications, and mechanisms of biological organization, including the discovery of phosphoethanolamine (pEtN) cellulose, a chemically modified form of cellulose that fundamentally changed our understanding of bacterial extracellular matrices.
In parallel, we discover and engineer molecules that probe, disrupt, and control biological systems. A major focus is the development of new strategies to combat antibiotic resistance and persistent bacterial communities. Our laboratory has introduced first-in-class vancomycin conjugates with multiple modes of action, unusually broad-spectrum activity, and the ability to sterilize biofilms - properties not observed together in other vancomycin conjugates. We also develop anti-biofilm agents, molecular probes, imaging agents, and other chemical tools that both reveal new biology and provide starting points for addressing pressing challenges in human health and disease.
Together, our research spans fundamental chemical discovery and molecular invention: uncovering the chemistry that enables biological systems to assemble and persist, and using those insights to create new ways to interrogate and control them. This work opens opportunities to combat infectious disease, improve human health, preserve marine ecosystems, advance sustainable materials, and deepen our understanding of how chemistry organizes life. -
Sierra Mei Lin Centkowski, MD
Clinical Assistant Professor, Dermatology
BioDr. Sierra Mei Lin Centkowski is a board-certified Clinical Assistant Professor of Dermatology at Stanford University. She received both her medical degree and Master’s in Bioethics from the Perelman School of Medicine at the University of Pennsylvania and completed her dermatology residency at Stanford. Her clinical interests include general dermatology, including skin cancer, acne, psoriasis, atopic dermatitis and dermatologic surgery. She believes that patient empowerment and partnership provide the foundation for effective, compassionate and holistic care.
-
Alma-Martina Cepika
Assistant Professor of Surgery (General Surgery)
Current Research and Scholarly InterestsCepika Lab studies human immune tolerance. Using cellular immunology, genomics, and gene engineering, we aim to understand: 1) the role of human thymic regulatory T cells (Tregs) and inducible type 1 regulatory T (Tr1) cells in resistance to anti-tumor immunity and cancer immunotherapy, and 2) the interplay between innate and adaptive immunity in the pathogenesis of human inflammatory bowel disease (IBD). Our overarching goal is to leverage our discoveries for improving patient outcomes.
